Statin—Fibrate Combination Therapy

@article{Shek2001StatinFibrateCT,
  title={Statin—Fibrate Combination Therapy},
  author={A Shek and Mary J. Ferrill},
  journal={Annals of Pharmacotherapy},
  year={2001},
  volume={35},
  pages={908 - 917}
}
BACKGROUND: Precautionary warnings for severe myopathy and rhabdomyolysis from the coadministration of statins and fibrates have been well publicized. However, a recent cerivastatin labeling change made the combined use with fibric acid derivatives a contraindication. Practical recommendations for clinicians who care for patients with refractory mixed hyperlipidemia are needed. OBJECTIVE: To provide recommendations for clinicians in the treatment of refractory mixed hyperlipidemia. DATA SOURCES… Expand
A Clinical Review of Statin-Associated Myopathy
TLDR
Statin-associated myopathy is a clinical problem that contributes to statin therapy discontinuation and patients who are statin intolerant may be treated with alternative treatment options such as low-dose statins, switching statin, using alternative dosing strategies in statins with longer half-lives, non-statin lipid-lowering agents, and complementary therapies. Expand
Risk Factors and Drug Interactions Predisposing to Statin-Induced Myopathy
TLDR
The identification of patients with an increased proclivity to statin-induced myopathy could allow more cost-effective approaches of monitoring and screening, facilitate targeted prevention of potential complications, and further improve the already overwhelmingly positive benefit-risk ratio of statins. Expand
Simvastatin–Fluconazole Causing Rhabdomyolysis
TLDR
Patients receiving statins who have cancer may receive azole antifungals and other drugs that inhibit CYP3A4 during treatment, predisposing them to toxicity, and patients should be monitored closely for drug interactions. Expand
Risk for myopathy with statin therapy in high-risk patients.
TLDR
Clinicians should be alert to the potential for drug-drug interactions to minimize the risk of myopathy during long-term statin therapy in patients at high risk for coronary heart disease. Expand
Safety considerations with fibrate therapy.
TLDR
Clinicians are advised to measure serum creatinine before fibrate use and adjust the dose accordingly for renal impairment, and if a patient has a clinically important increase in Creatinine, consideration should be given to discontinuing fibrates or reducing the dose. Expand
Rhabdomyolysis associated with hydroxymethylglutaryl-coenzyme A reductase inhibitors☆
TLDR
The cerivastatin experience emphasizes the need for large safety trials before drug approval and for vigilant post-marketing surveillance, and may lead to the identification of high-risk individuals in whom statins should be avoided. Expand
Statin-fibrat kombinasyon tedavisi
TLDR
The role of combined statin-fibrate therapy in dyslipidemia, their mechanisms of action, efficacy and safety, and precautions needed to be taken to reduce side effects are reviewed in the light of literature. Expand
Rhabdomyolysis and statin therapy: relevance to the elderly.
  • D. Sica, T. Gehr
  • Medicine
  • The American journal of geriatric cardiology
  • 2002
TLDR
Physicians must take many factors into account when selecting a member of the HMG-CoA reductase inhibitor class, particularly as relates to their use in the multiply medicated elderly patient. Expand
Current overview of statin-induced myopathy.
TLDR
Since myotoxic events are more frequent at higher doses, statins that are effective in reducing cholesterol levels and helping patients to reach target levels at start doses may be useful. Expand
[Is every case of muscle damage during hypolipemic therapy the side effect of this therapy? A case report].
TLDR
It is considered that hypolipemic treatment probably revealed previously occult autoimmune thyroid disease in this patient, and the introduction of thyroid hormone supplementation led to regression of symptoms and normalization of abnormalities found in laboratory examinations including remarkable improvement in lipid profile. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 101 REFERENCES
Rhabdomyolysis and acute renal failure associated with gemfibrozil therapy.
TLDR
A case of rhabdomyolysis and acute renal failure in a patient receiving gemfibrozil as the only lipidlowering agent, and in absence of any other drug or clinical condition recognized as cause of r rehabilitation, is reported. Expand
Treatment of hyperlipidemia with combined niacin-statin regimens.
TLDR
This combination therapy can be used safely as long as careful attention is given to niacin formulation and dosing; liver functions are monitored; and patients are educated to recognize symptoms of myopathy. Expand
Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy.
TLDR
The use of lovastatin in combination with gemfibrozil is to be discouraged because of the potential for severe myopathy and life-threatening rhabdomyolysis. Expand
Addition of fibrates to simvastatin therapy in hyperlipidaemic patients
TLDR
A long-term study to investigate combination therapy with simvastatin and bezafibrate in patients with either familial hypercholesterolaemia or combined hyperlipidaemia and found that this side-effect appears to be rare. Expand
TOLERABILITY AND EFFICACY OF COMBINATION THERAPY WITH SIMVASTATIN PLUS GEMFIBROZIL IN TYPE IIb REFRACTORY FAMILIAL COMBINED HYPERLIPIDEMIA
TLDR
The tolerability and efficacy of combined simvastatin plus gemfibrozil therapy was investigated over 18 months in 20 patients at high risk for atherosclerosis affected by type IIb FCH, and optimum therapy was maintained. Expand
Rhabdomyolysis associated with simvastatin-gemfibrozil therapy.
TLDR
A case of severe myopathy and rhabdomyolysis associated with concomitant use of simvastatin and gemfibrozil is described. Expand
Treatment of severe, resistant familial combined hyperlipidemia with a bezafibrate-lovastatin combination.
TLDR
The bezafibrate-lovastatin combination is a possible therapeutic option for severe, resistant FCHL, but close medical supervision is needed because of potential side effects. Expand
Treatment of combined hyperlipidemia with fluvastatin and gemfibrozil, alone or in combination, does not induce muscle damage.
TLDR
Although combination therapy using HMG-Co-A reductase inhibitors and fibrates is efficacious in combined hyperlipidemia, such treatment has been associated with myopathy, and the effects of fluvastatin and gemfibrozil, alone or in combination, on muscle are studied. Expand
Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders.
TLDR
Combinations of gemfibrozil and an HMG, compared with either agent alone, results in improved long-term control of lipid abnormalities in mixed lipid disorders. Expand
Lovastatin/gemfibrozil myopathy: a clinical, histochemical, and ultrastructural study.
TLDR
A 57-year-old woman with hyperlipidemia, treated with lovastatin and gemfibrozil, was admitted to the hospital for evaluation of muscular weakness in her legs and neck who developed a rapidly progressive necrotizing myopathy. Expand
...
1
2
3
4
5
...